SurModics (SRDX) Sundance Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to SurModics (SRDX) Sundance Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status

SurModics (SRDX) Reports In-Line Q4 EPS, Revenues Beat; Offers FY20 EPS/Revenue Guidance Below Consensus

October 31, 2019 4:17 PM EDT

SurModics (NASDAQ: SRDX) reported Q4 EPS of $0.37, in-line with the analyst estimate of $0.37. Revenue for the quarter came in at $30.8 million versus the consensus estimate of $28.36 million.

Summary of Fourth Quarter and Recent Highlights

Revenue of $30.8 million, an increase of 33.8% year-over-yearGAAP EPS of $0.26, non-GAAP EPS of $0.37Completed enrollment in TRANSCEND pivotal clinical trial for... More